Arch Therapeutics (OTCMKTS:ARTH) is engaged in the development and marketing of self-assembling devices which are meant for wound care and also for buisurgeries.
Trading Data
On Wednesday, ARTH stock gained 1.32% at $0.0999 with more 277k shares, compared to its average volume of 225K shares. The stock has moved within a range of $0.0949 – 0.0999 after opening trade at $0.0986.
Adds Key Opinion Leader Interview on Diabetic Foot Ulcers to the Experts in Wound Care Program
Yesterday, the company was in the news after it made a key announcement but it did not do much for the Arch Therapeutics stock, which continued to trade within a range. The company announced yesterday that it managed to bring in a Key Opinion Leader interview to the Experts in Wound Care Program that it is promoting. It was a major announcement from the company but it did not lead to any particularly enthusiasm about the Arch Therapeutics stock among investors.
In this initiative, a number of interviews are going to be produced with important opinion makers who are involved in the world of wound care.
The company noted that it roped in opinion leader Dr Christopher Gauland for this purpose. The interview in question is titled “Preventing Diabetic Foot Ulcers and How AC5® Advanced Wound System Can Help” and Gauland is going to speak on that topic. At this point in time, it might be a good move from investors to keep an eye on the Arch Therapeutics stock. Stocks trading within a range can also breakout strongly.
